Baird on BioMarin Pharmaceutical Inc. (BMRN): 'Incrementally negative on competitor data'
Tweet Send to a Friend
Baird analyst Jack Allen reiterated a Neutral rating and $65.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
